Aspirin for primary cardiovascular disease prevention: what we know and what we don't know

Intern Med J. 2019 Jan;49(1):12-14. doi: 10.1111/imj.14190.

Authors

Ning Song^{1

2}, John K French^{2

3

4}

Affiliations

¹ Department of Cardiology, St Vincent's Hospital, Sydney, New South Wales, Australia.
² School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
³ Department of Cardiology, Liverpool Hospital, Sydney, New South Wales, Australia.
⁴ School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.

PMID: 30680899
DOI: 10.1111/imj.14190

No abstract available

Publication types

Editorial

MeSH terms

Aspirin / therapeutic use*
Cardiovascular Diseases / prevention & control*
Fibrinolytic Agents / therapeutic use*
Humans
Primary Prevention

Substances

Fibrinolytic Agents
Aspirin